You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 29, 2026

Details for New Drug Application (NDA): 021227

✉ Email this page to a colleague

NDA 021227 describes CANCIDAS, which is a drug marketed by Merck and is included in one NDA. It is available from one supplier. Additional details are available on the CANCIDAS profile page.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

Summary for 021227

Tradename:	CANCIDAS
Applicant:	Merck
Ingredient:	caspofungin acetate
Patents:	0

Pharmacology for NDA: 021227

Suppliers and Packaging for NDA: 021227

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227	NDA	Merck Sharp & Dohme LLC	0006-3822	0006-3822-10	1 VIAL, SINGLE-USE in 1 CARTON (0006-3822-10) / 10.8 mL in 1 VIAL, SINGLE-USE
CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227	NDA	Merck Sharp & Dohme LLC	0006-3823	0006-3823-10	1 VIAL, SINGLE-USE in 1 CARTON (0006-3823-10) / 10.8 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;INTRAVENOUS			Strength	50MG/VIAL
Approval Date:	Jan 26, 2001	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;INTRAVENOUS			Strength	70MG/VIAL
Approval Date:	Jan 26, 2001	TE:		RLD:	Yes

Expired US Patents for NDA 021227

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	6,136,783*PED	⤷ Get Started Free
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	5,378,804*PED	⤷ Get Started Free
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	5,952,300*PED	⤷ Get Started Free
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	6,136,783*PED	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.